Patient leaflet - Epivir 300 mg film-coated tablets
1 What Epivir is and what it is used for
Epivir is used to treat HIV (human immunodeficiency virus) infection in adults and children.
The active ingredient in Epivir is lamivudine. Epivir is a type of medicine known as an anti-retroviral. It belongs to a group of medicines called nucleoside analogue reverse transcriptase inhibitors (NRTIs).
Epivir does not completely cure HIV infection; it reduces the amount of virus in your body and keeps it at a low level. It also increases the CD4 cell count in your blood. CD4 cells are a type of white blood cells that are important in helping your body to fight infection.
Not everyone responds to treatment with Epivir in the same way. Your doctor will monitor the effectiveness of your treatment.
2 What you need to know before you take Epivir
Do not take Epivir:
- if you are allergic to lamivudine or any of the other ingredients in this medicine (listed in Section 6).
➔ Check with your doctor if you think this applies to you.
Take special care with Epivir
Some people taking Epivir or other combination treatments for HIV are more at risk of serious side effects. You need to be aware of the extra risks:
- if you have ever had liver disease, including hepatitis B or C (if you have hepatitis B infection, do not stop Epivir without your doctor’s advice, as your hepatitis may come back)
- if you are seriously overweight (especially if you are a woman)
- if you have a kidney problem, your dose may be altered.
➔ Talk to your doctor if any of these apply to you. You may need extra
check-ups, including blood tests, while you are taking your medicine. See Section 4 for more information.
Look out for important symptoms
Some people taking medicines for HIV infection develop other conditions, which can be serious. You need to know about important signs and symptoms to look out for while you are taking Epivir.
➔ Read the information ‘Other possible side effects of combination therapy for HIV’ in Section 4 of this leaflet.
Other medicines and Epivir
Tell your doctor or pharmacist if you are taking any other medicines, or if you have taken any recently, including herbal medicines or other medicines you bought without a prescription.
Remember to tell your doctor or pharmacist if you begin taking a new medicine while you are taking Epivir.
These medicines should not be used with Epivir:
- medicines (usually liquids) containing sorbitol and other sugar alcohols (such as xylitol, mannitol, lactitol or maltitol), if taken regularly
- other medicines containing lamivudine, (used to treat HIV infection or hepatitis B infection)
- emtricitabine (used to treat HIV infection)
- high doses of co-trimoxazole, an antibiotic
- cladribine (used to treat hairy cell leukaemia).
➔ Tell your doctor if you are being treated with any of these.
Pregnancy
If you are pregnant, if you become pregnant, or are planning to become pregnant, talk to your doctor about the risks and benefits to you and your baby of taking Epivir.
Epivir and similar medicines may cause side effects in unborn babies. If you have taken Epivir during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child. In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.
Breast-feeding
Breast-feeding is not recommended in women living with HIV because HIV infection can be passed on to the baby in breast milk.
A small amount of the ingredients in Epivir can also pass into your breast milk. If you are breast-feeding, or thinking about breast-feeding, you should discuss it with your doctor as soon as possible.
Driving and using machines
Epivir is unlikely to affect your ability to drive or use machines.
Epivir contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially ‘sodium-free’.
3 How to take Epivir
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Swallow the tablet with some water. Epivir can be taken with or without food. If you cannot swallow the tablet whole, you may crush and combine it with a small amount of food or drink, and take all the dose immediately.
Stay in regular contact with your doctor
Epivir helps to control your condition. You need to keep taking it every day to stop your illness getting worse. You may still develop other infections and illnesses linked to HIV infection.
➔ Keep in touch with your doctor, and do not stop taking Epivir without your doctor’s advice.
How much to take
Adults, adolescents and children who weigh at least 25 kg: The usual dose is one 300 mg tablet once a day.
A 150 mg strength Epivir tablet is also available for the treatment of children from 3 months of age who weigh less than 25 kg:
An oral solution is also available for the treatment of children over 3 months of age, or for people who need a lower dose than usual, or who cannot take tablets. If you have a kidney problem, your dose may be altered. ➔ Talk to your doctor if this applies to you.
If you take more Epivir than you should
If you take too much Epivir, tell your doctor or your pharmacist, or contact your nearest hospital emergency department for further advice. If possible, show them the Epivir pack.
If you forget to take Epivir
If you forget to take a dose, take it as soon as you remember. Then continue your treatment as before. Do not take a double dose to make up for a forgotten dose. 200003078
Production Site:
Delpharm_Poznan_POLAND
Leaflet - flat dimensions (width x height):
148 x 608 mm
folded dimensions (width x height): N/A
Foil / Laminate - dimensions (width):
N/A
random repeats:
N/A
Carton - dimensions (width x height x depth):
N/A
Tube - dimensions (Ø, length):
N/A
Label - dimensions (width x height): N/A
200002467
Point of Sale Code Number:
N/A
and pre-press suitability.
GSK Market is responsible to advise SDC when changes
required impact the following:
Formulation, Tablet embossing, Storage conditions and Shelf Life
NOTE TO MARKET
Local approvers must ensure that trade mark and copyright statements included in the brief comply with guidance provided by
Legal: Global Trade Marks.
Manufacturing Site Number:
200003078
Manufacturing Site(s):
Delpharm_Poznan_POLAND
DRW_L_020_01_FD
Product Market Trade Name:
EPIVIR
Approving Market(s):
United Kingdom-GBR
Material Spec: (Do NOT include version number):
N/A
N/A
Colour Standard Reference:
N/A
Material Type:
N/A N/A
9.0pt
9.0pt
Leading:
10.0pt
Horizontal Scale:
100%
Microtext:
N
2
BLACK 569
0
Additional Info (1):
N/A
Additional Info (2):
N/A
Additional Info (3):
N/A
200 mm Measuring Bar Artwork copyright is the property of the GSK Group of Companies. All suppliers providing a service to GSK for printed components of any description must ensure that they have a licence for all fonts / software used in conjunction with GSK artwork. The distribution and use of fonts / software without a licence constitutes an intellectual property infringement. GSK will not accept any liability for the breach of third party intellectual property rights by printed component suppliers. The GSK certification / audit process requires suppliers to declare that they do not use unlicensed fonts / software and may require the supplier to produce evidence of such licence to GSK.
4 Possible side effects
During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves. Your doctor will test for these changes.
Like all medicines, this medicine can cause side effects, but not everyone gets them.
When you are being treated for HIV, it can be hard to tell whether a symptom is a side effect of Epivir or other medicines you are taking, or an effect of the HIV disease itself. So it is very important to talk to your doctor about any changes in your health.
As well as the side effects listed below for Epivir, other conditions can develop during combination therapy for HIV.
➔ It is important to read the information later in this section under ‘Other
possible side effects of combination therapy for HIV’.
Common side effects
These may affect up to 1 in 10 people:
- headache
- feeling sick (nausea)
- being sick (vomiting)
- diarrhoea
- stomach pains
- tiredness, lack of energy
- fever (high temperature)
- general feeling of being unwell
- muscle pain and discomfort
- joint pain
- difficulty in sleeping (insomnia)
- cough
- irritated or runny nose
- rash
hair loss (alopecia).
Uncommon side effects
These may affect up to 1 in 100 people:
Uncommon side effects that may show up in blood tests are:
- a decrease in the number of cells involved in blood clotting (thrombocytopenia)
- a low red blood cell count (anaemia) or low white blood cell count (neutropenia)
- an increase in the level of liver enzymes.
Rare side effects
These may affect up to 1 in 1000 people:
- serious allergic reaction causing swelling of the face, tongue or throat which may cause difficulty in swallowing or breathing
- inflammation of the pancreas (pancreatitis)
- breakdown of muscle tissue
- inflammation of the liver (hepatitis).
A rare side effect that may show up in blood tests is:
- increase in an enzyme called amylase.
Very rare side effects
These may affect up to 1 in 10,000 people:
- Lactic acidosis (excess lactic acid in the blood)
- tingling or numbness of the arms, legs, hands or feet. A very rare side effect that may show up in blood tests is:
- a failure of the bone marrow to produce new red blood cells (pure red cell aplasia).
If you get side effects
➔ Tell your doctor or pharmacist if any of the side effects gets severe or
troublesome, or if you notice any side effects not listed in this leaflet.
Other possible side effects of combination therapy for HIV
Combination therapy including Epivir may cause other conditions to develop during HIV treatment.
Old infections may flare up
People with advanced HIV infection (AIDS) have weak immune systems and are more likely to develop serious infections (opportunistic infections). When these people start treatment, they may find that old, hidden infections flare up, causing signs and symptoms of inflammation. These symptoms are probably caused by the body’s immune system becoming stronger, so that the body starts to fight these infections.
In addition to the opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection. Autoimmune disorders may occur many months after the start of treatment. If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment.
If you get any symptoms of infection while you are taking Epivir:
➔ Tell your doctor immediately. Do not take other medicines for the
infection without your doctor’s advice.
You may have problems with your bones
Some people taking combination therapy for HIV develop a condition called osteonecrosis. With this condition, parts of the bone tissue die because of reduced blood supply to the bone. People may be more likely to get this condition:
- if they have been taking combination therapy for a long time
- if they are also taking anti-inflammatory medicines called corticosteroids
- if they drink alcohol
- if their immune systems are very weak
if they are overweight.
Signs of osteonecrosis include:
- stiffness in the joints
- aches and pains (especially in the hip, knee or shoulder)
- difficulty moving.
If you notice any of these symptoms:
➔ Tell your doctor.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
5 How to store Epivir
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton. Do not store Epivir above 30°C.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away the medicines you no longer use. These measures will help to protect the environment.
6 Contents of the pack and other information
What Epivir contains
The active substance is lamivudine.
The tablets also contain the following other ingredients:
Tablet core: microcrystalline cellulose, sodium starch glycollate (gluten free), magnesium stearate
Film-coat: hypromellose, titanium dioxide, black iron oxide (E172), macrogol, polysorbate 80
What Epivir looks like and the contents of the pack
Epivir 300 mg film-coated tablets are supplied in white polyethylene bottles or blister packs containing 30 tablets. They are grey, diamond shaped film-coated tablets, marked with the code ‘GXEJ7’ on one side.
Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder
ViiV Healthcare UK Limited
79 New Oxford Street
London
WC1A 1DG
United Kingdom
Manufacturer
Delpharm Poznań Spółka Akcyjna ul. Grunwaldzka 189
60-322 Poznan
Poland
Other formats
To listen to or request a copy of this leaflet in Braille, large print or audio please call, free of charge:
0800 198 5000 (UK Only)
Please be ready to give the following information:
Product name Epivir 300 mg Film-coated tablets
Reference number 35728/0033
This is a service provided by the Royal National Institute of Blind People.
This leaflet was last revised in March 2025.
Trade marks are owned by or licensed to the ViiV Healthcare group of companies. ©2025 ViiV Healthcare group of companies or its licensor.
200003078
Production Site:
Delpharm_Poznan_POLAND
Leaflet - flat dimensions (width x height):
148 x 608 mm
folded dimensions (width x height): N/A
Foil / Laminate - dimensions (width):
N/A
random repeats:
N/A
Carton - dimensions (width x height x depth):
N/A
Tube - dimensions (Ø, length):
N/A
Label - dimensions (width x height): N/A
200002467
Point of Sale Code Number:
N/A
and pre-press suitability.
GSK Market is responsible to advise SDC when changes
required impact the following:
Formulation, Tablet embossing, Storage conditions and Shelf Life
NOTE TO MARKET
Local approvers must ensure that trade mark and copyright statements included in the brief comply with guidance provided by
Legal: Global Trade Marks.
Manufacturing Site Number:
200003078
Manufacturing Site(s):
Delpharm_Poznan_POLAND
DRW_L_020_01_FD
Product Market Trade Name:
EPIVIR
Approving Market(s):
United Kingdom-GBR
Material Spec: (Do NOT include version number):
N/A
N/A
Colour Standard Reference:
N/A
Material Type:
N/A N/A
9.0pt
9.0pt
Leading:
10.0pt
Horizontal Scale:
100%
Microtext:
N
2
BLACK 569
0
Additional Info (1):
N/A
Additional Info (2):
N/A
Additional Info (3):
N/A
200 mm Measuring Bar Artwork copyright is the property of the GSK Group of Companies. All suppliers providing a service to GSK for printed components of any description must ensure that they have a licence for all fonts / software used in conjunction with GSK artwork. The distribution and use of fonts / software without a licence constitutes an intellectual property infringement. GSK will not accept any liability for the breach of third party intellectual property rights by printed component suppliers. The GSK certification / audit process requires suppliers to declare that they do not use unlicensed fonts / software and may require the supplier to produce evidence of such licence to GSK.